Related Experiment Video
Updated: Jun 19, 2026

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
Tuberculin conversion and leukocyte migration inhibition test after BCG vaccination in newborn infants
Mma Faridi1, Sarvpreet Kaur, Sriram Krishnamurthy
1Division of Neonatology, Department of Pediatrics, University College of Medical Sciences, University of Delhi and Guru Tegh Bahadur Hospital, New Delhi, India. drmmafaridi@gmail.com
Insights
BCG vaccination is effective in preterm and low birth weight infants, but tuberculin conversion is an unreliable indicator of immune response. Local BCG reactions at 8 weeks better reflect cell-mediated immunity.
Area of Science:
- Immunology
- Pediatrics
- Vaccinology
Background:
- Reports suggest suboptimal BCG vaccine uptake in preterm and low birth weight neonates.
- Assessing BCG vaccine efficacy in vulnerable infant populations is crucial for global tuberculosis control.
Purpose of the Study:
- To evaluate BCG vaccine take-up via tuberculin conversion using the Mantoux test at 12 weeks and 6 months.
- To assess the utility of the Leukocyte Migration Inhibition Test (LMIT) in BCG-vaccinated infants with negative Mantoux tests.
Main Methods:
- A prospective observational study involving 143 neonates (31-41 weeks gestation) vaccinated with BCG within 7 days of birth.
- Mantoux testing at 12 weeks and 6 months, with LMIT performed on Mantoux-negative infants.
- Follow-up included repeat Mantoux and LMIT tests to assess immune response over time.
Main Results:
- 95.5% of infants showed local BCG reactions at 8 weeks; 47.2% developed scars by 12 weeks.
- Tuberculin conversion rates were 42.7% at 12 weeks and increased to 66.4% by 6 months.
- LMIT was positive in 84.1% of Mantoux-negative infants at 12 weeks, indicating cellular immunity.
Conclusions:
- BCG vaccination is effective in preterm (31-36 weeks) and low birth weight (<2500g) infants.
- Tuberculin conversion is not a reliable sole indicator of BCG vaccine response.
- Local BCG reactions and LMIT provide better assessments of cell-mediated immunity post-vaccination.
Background:
There are reports that BCG vaccine take-up may be delayed or poor among preterm and low birth weight babies
Objective:
The present study was conducted with the objective of (a) studying BCG take-up through tuberculin conversion by Mantoux test at 12 weeks and 6 months of age in babies vaccinated with BCG at birth and (b) evaluating the Leukocyte Migration Inhibition Test (LMIT) in BCG vaccinated babies who did not react to Mantoux test.
Design:
Prospective observational study.
Methods:
BCG vaccine was administered to 143 neonates of 31-41 weeks gestation within 7 days of birth. At 12 weeks of age, Purified Protein Derivative (1 TU PPD-RT 23 with Tween 80) was injected to all the babies and induration was measured at the injection site after 48 hours. Mantoux negative babies were subjected to the LMIT. All the Mantoux test and LMIT negative babies were followed up and given another Mantoux test at 6 months. Those babies who showed a negative Mantoux test at 6 months and negative LMIT at 12 weeks were subjected to another LMIT at 6 months.
Results:
Local BCG reaction was exhibited by 95.5% babies at 8 weeks and scar formed in 47.2% of them by 12(+1) weeks. The tuberculin conversion rate after 12 weeks of BCG vaccination was 42.7%. The rate of tuberculin conversion was significantly more in babies with birth weight>2500 g as compared to low birth weight babies. Also, the rate of tuberculin conversion was significantly more in term infants as compared to preterm babies. Six months after BCG vaccination, 41.5% of previously Mantoux negative babies showed tuberculin conversion. Overall, 66.4% babies reacted to PPD after 6 months. LMIT was positive in 84.1% babies who had a negative Mantoux test at 12 weeks. Six months after BCG vaccination, 53.8% of babies who had LMIT negative at 3 months became LMIT positive. Thus out of 143 babies, 95.8% had either a reactive Mantoux test or positive LMIT 6 months after BCG vaccination. There were only 6 babies (4.2%) who did not show adequate responses to BCG vaccination.
Conclusion:
Preterm babies of 31 to 36 weeks of gestation and low birth weight babies weighing <2,500 gram at birth can be effectively vaccinated with BCG vaccine in the early neonatal period. However, tuberculin conversion is not a reliable indicator to assess responses induced by BCG vaccination either 12 weeks or 6 months after vaccination because inspite of negative Mantoux test, the vaccinated infant may still be having an adequate response to BCG vaccine. The local BCG reaction at 8 weeks corresponds to cell mediated immunity conferred by BCG vaccination.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:

